506238 Citalopram Hydrobromide - CAS 59729-32-7 - Calbiochem

506238
View Pricing & Availability

Overview

Replacement Information

Key Specifications Table

Empirical FormulaCAS #
C₂₀H₂₁FN₂O·HBr 59729-32-7

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
5.06238.0001
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Glass bottle 25 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity needs to be mulitiple of
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA potent uptake inhibitor highly selective for 5-HT transporter without effect on noradrenalin or dopamine uptake (IC50 = 1.8, 8800 and 41000 nM for 5-HT, noradrenalin and dopamine, respectively). Clinically prescribed as an antidepressant drug. Widely used in research related to depressive disorders.
      Catalogue Number506238
      Brand Family Calbiochem®
      Synonyms5-HT Transporter Inhibitor, Citalopram, Celexa
      References
      ReferencesGarriock, A., et al., 2010. Bio. Psychiatry. 67, 133.
      Gabriel, J.P., et al. 2009. J. Neurosci. 29,10387.
      Torres, G.E., et al. 2003. Nat. Rev. Neurosci. 4, 13.
      Product Information
      CAS number59729-32-7
      FormWhite solid
      Hill FormulaC₂₀H₂₁FN₂O·HBr
      Chemical formulaC₂₀H₂₁FN₂O·HBr
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Target5-HT Transporter
      Primary Target IC<sub>50</sub>1.8 nM
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 22

      Harmful if swallowed.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Harmful
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Citalopram Hydrobromide - CAS 59729-32-7 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      References

      Reference overview
      Garriock, A., et al., 2010. Bio. Psychiatry. 67, 133.
      Gabriel, J.P., et al. 2009. J. Neurosci. 29,10387.
      Torres, G.E., et al. 2003. Nat. Rev. Neurosci. 4, 13.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision15-November-2013 JSW
      Synonyms5-HT Transporter Inhibitor, Citalopram, Celexa
      DescriptionA potent uptake inhibitor highly selective for 5-HT transporter without effect on noradrenalin or dopamine uptake (IC50 = 1.8, 8800 and 41000 nM for 5-HT, noradrenalin and dopamine, respectively). Clinically prescribed as an antidepressant drug. Widely used in research related to depressive disorders.
      FormWhite solid
      CAS number59729-32-7
      Chemical formulaC₂₀H₂₁FN₂O·HBr
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityEthanol (50 mM) or H₂O (10 mM)
      Storage +2°C to +8°C
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Harmful
      ReferencesGarriock, A., et al., 2010. Bio. Psychiatry. 67, 133.
      Gabriel, J.P., et al. 2009. J. Neurosci. 29,10387.
      Torres, G.E., et al. 2003. Nat. Rev. Neurosci. 4, 13.